Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Real-time Boerse Muenchen 14:44:13 25/09/2025 HKT			5-day change	1st Jan Change
0.0985 ^EUR	-0.51%		-.--%	-

09-01	CARMAT SAS Publishes Results Of EFICAS Clinical Study On Aeson Total Artificial Heart As Bridge-To-Transplant Therapy	CI
01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris

Market Cap	6.15M 7.13M 5.82M 5.27M 9.9M 681M 9.95M 69.11M 26.58M 347M 26.79M 26.2M 1.1B	P/E 2023	-3.09x	P/E 2024	-0.95x
Enterprise Value	59.25M 68.76M 56.1M 50.85M 95.39M 6.57B 95.88M 666M 256M 3.34B 258M 253M 10.56B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

09-01	CARMAT SAS Publishes Results Of EFICAS Clinical Study On Aeson Total Artificial Heart As Bridge-To-Transplant Therapy	CI
01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-07	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-07	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-05	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
16/10/25	CAC 40 Surges on LVMH Results and Easing US-China Tensions
15/10/25	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
15/10/25	Carmat says liquidation review postponed until Nov 25	RE
01/10/25	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE

09/05/25	Carmat: Invest Securities raises target price
11/04/25	Carmat: Invest Securities still a buyer, but cuts TP
04/02/25	Carmat: Invest Securities slightly lowers its target
09/01/25	Carmat: Invest Securities upgrades to buy
09/01/25	Carmat: Oddo BHF reduces its price target

CARMAT Stock Boerse Muenchen

Stocks

CXT

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation : CARMAT

Chart: CARMAT

Latest news : CARMAT

Analysts' recommendations : CARMAT

Press Releases : CARMAT

News in other languages : CARMAT

Quotes and Performance

Managers and Directors : CARMAT

Medical Devices & Implants

Financials

Company Profile

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-05	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
29/10/25	CARMAT : Inside Information / Other news releases	PU
29/10/25	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
15/10/25	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	01/09/2016
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	12/12/2018
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	01/04/2025

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	02/01/2017
Michael Mack BRD	Director/Board Member	79	20/04/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-0.51%	-.--%	-	-	7.08M
STRYKER CORPORATION	+0.82%	-10.33%	-30.08%	-9.31%	104B
SMITH & NEPHEW PLC	-1.66%	-5.22%	-29.15%	-5.53%	11.67B
GLAUKOS CORPORATION	-0.60%	-4.32%	+94.14%	+123.52%	10.04B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-1.34%	-3.93%	-55.03%	-71.49%	3.99B
DOUBLE MEDICAL TECHNOLOGY INC.	-2.84%	-6.02%	-30.57%	+30.74%	2.4B
INSPIRE MEDICAL SYSTEMS, INC.	+3.62%	+12.35%	-14.41%	-68.30%	1.97B
INSIGHT LIFETECH CO., LTD.	+1.47%	-6.79%	-	-	1.81B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-2.10%	-3.88%	-24.51%	-29.82%	1.53B
Average	-0.33%	-3.81%	-12.80%	-4.31%	17.12B
Weighted average by Cap.	+0.32%	-10.17%	-21.23%	-1.32%

	2023	2024
Net sales	3.84M 4.45M 3.63M 3.29M 6.18M 425M 6.21M 43.15M 16.59M 216M 16.72M 16.36M 684M	7.34M 8.52M 6.95M 6.3M 11.82M 814M 11.88M 82.59M 31.76M 414M 32.01M 31.31M 1.31B
Net income	-53.87M -62.52M -51.01M -46.23M -86.73M -5.97B -87.17M -606M -233M -3.04B -235M -230M -9.6B	-51.4M -59.65M -48.66M -44.11M -82.75M -5.7B -83.17M -578M -222M -2.9B -224M -219M -9.16B
Net Debt	49.64M 57.61M 47M 42.6M 79.92M 5.5B 80.32M 558M 215M 2.8B 216M 212M 8.85B	53.1M 61.63M 50.28M 45.57M 85.5M 5.89B 85.93M 597M 230M 3B 231M 226M 9.47B